CZG LAB
Contact Us

Tel:008613815056465

Fax:0086-0519-86474295

Mobile phone:0086-18861115105

ADD:HongKong Central Stanley Street

Email:info@czgeneral.com

Home  >  News  >  PT-141 Bremelanotide
PT-141 Bremelanotide
Friday 10th November 2017

PT-141

Bremelanotide (PT-141) is a peptide drug developed by Palatin Technologies and it is mainly used as a treatment for female sexual dysfunction (FSD), male erectile dysfunction (ED), hemorrhagic shock and reperfusion injury.

How does bremelanotide work?

Bremelanotide increases sexual desire through the activation in brain of the MC4 receptor, which regulates the metabolism, the sexual behavior and the male erectile function. Its operating mechanism involves an action in the central nervous system rather than directly on the vascular system.

PT-141 results

Initially Bremelanotide was conceived as a sunless tanning agent and had its origins from the melanotan II peptide hormone, which is a synthetic analogue of the naturally occurring melanocortin peptide hormone that is used to produce melanogeseis (the production of a pigment found in the skin, eyes and hair called melanin). Nevertheless, Bremelanotide has caused sexual arousal and spontaneous male erections during testing, which showed the potential of this peptide as an effective treatment of sexual dysfunction in both men and woman.

In men, this peptide is used as a treatment of erectile dysfunction (the inability to develop or maintain an erection of the penis during sexual activity). An erection is accomplished while blood enters and is retained in sponge-like bodies within the penis because of sexual arousal. Due to the brain is in charge of transmitting signals to nerves in the penis, the stimulation of this process causes an erection through the use of Bremelanotide.

Bremelanotide is an effective treatment for arousal disorder, which is characterized by the lack or absence of desire for sexual activity in a situation that would normally produce a response to the stimulus. This disorder can be caused physically because of circulatory problems or alterations in neurological functions where low levels of libido (desire for sexual activity) are observed. Libido is regulated both by the sex hormones and the associated neurotransmitter that act upon testosterone and dopamine.